G01N2021/6439

ANTI-PD-L1 ANTIBODIES AND METHODS OF USING THE SAME FOR DETECTION OF PD-L1

The present application relates to anti-PD-L1 antibodies and their use to detect PD-L1 in a sample from a subject. In some embodiments, the subject has been treated with a therapeutic anti-PD-L1 antibody and an anti-PD-L1 described herein does not compete for binding to PD-L1 with the therapeutic anti-PD-L1 antibody. In some embodiments, the anti-PD-L1 antibody is linked to a detectable moiety, such as a fluorophore and the anti-PD-L1 antibody is used to detect PD-L1 in a subject using flow cytometry.

SYSTEM AND METHOD FOR DETECTING PRESENCE OF A TARGET BIOPARTICLE IN A SAMPLE VIA A VERTICAL FLOW ASSAY

One variation of a system includes a cartridge comprising: a substrate; a sample well integrated into the substrate, defining an upper opening and a lower opening, and configured to receive a test solution comprising a user sample and an amount of a fluorescent probe configured to bind with a target bioparticle to form a target complex; a filter membrane extending across the lower opening and defining a network of pores configured to convey fluid from the sample well and prevent passage of the target complex through the filter membrane. The system further includes a reader comprising: a housing; a cartridge receptacle configured to receive the cartridge; an excitation source configured to illuminate a detection region within the housing; and a detector defining a field of view intersecting the detection region and configured to detect a signal generated by fluid in the sample well and representing presence of the target bioparticle.

DEVICE FOR RAPID AND QUANTITATIVE DETECTION OF DRUGS OF ABUSE IN SWEAT

An automated microfluidic bioreactor device and methods to rapidly detect drugs of abuse from human sweat are provided. The bioreactor can perform either single-plexed measurements (detecting only one target analyte at a time) or multiplexed measurement (detecting multiple analytes simultaneously). The bioreactor device has a cartridge comprising a capillary array that employs competitive enzyme-linked immunosorbent assay (ELISA) to detect the presence of various drugs or metabolite compounds. For example, four common drugs, methadone, methamphetamine, amphetamine, and tetrahydrocannabinol, were detected rapidly and quantitatively in about 16 minutes with a low sweat sample volume (about 4 μL per analyte) and a large dynamic range (methadone: 0.0016 ng/mL-1 ng/mL; METH: 0.016 ng/mL-25 ng/mL; amphetamine: 0.005 ng/mL-10 ng/mL; THC: 0.02 ng/mL-1000 ng/mL).

BIOLOGICAL SUBSTANCE DETECTION CHIP, BIOLOGICAL SUBSTANCE DETECTION DEVICE AND BIOLOGICAL SUBSTANCE DETECTION SYSTEM
20230047769 · 2023-02-16 ·

There is provided a biological substance detection chip having high detection accuracy. The present technology provides a biological substance detection chip which is composed of a plurality of pixels in which the pixel includes at least a holding surface on which a biological substance is held and a photoelectric conversion unit that is provided below the holding surface and provided on a semiconductor substrate, wherein a partition wall made of a conductor is provided between the pixels on the holding surface. In addition, the present technology provides a biological substance detection device and a biological substance detection system using the biological substance detection chip.

PIXEL-WISE POINT SPREAD FUNCTION ENGINEERING SYSTEMS AND METHODS
20230048370 · 2023-02-16 · ·

Systems, devices, and methods for producing an optimized phase mask for use in a single-molecule orientation localization microscopy (SMOLM) imaging system are disclosed.

Device and method for imaging shortwave infrared fluorescence

Systems and methods for measuring short wave infrared fluorescence and autofluorescent signals are disclosed. In some embodiments, for example, a method may include exposing a portion of tissue that does not include a fluorescent probe to an excitation source of the tissue, wherein at least a portion of the tissue has an autofluorescence spectrum which includes wavelengths greater than 900 nm, and imaging the tissue with a detector that is sensitive to electromagnetic radiation with wavelengths greater than or equal to 900 nm. In certain other embodiments, a system comprises a fluorescent probe including a fluorescent component attached to a carrier, an excitation source, and a detector that detects a tail portion of the fluorescence of the fluorescent component. Methods associated with such a system are also disclosed.

Method and device for the detection of carbapenemases and carbapenemase producers

The invention refers to a method and a device for the phenotypic detection of carbapenemases and carbapenemase producers by adding a substrate of general formula A-(L)-M.sub.1-(X)—Z, where M.sub.1 is a carbapenem backbone, A or Z is a quencher, the other one of the two, Z or A, is a fluorophore, L is an optional linker, X is an optional leaving group for linking Z to the carbapenem backbone, and Z is an optional leaving group, to a sample suspected of containing such carbapenemase producers and/or carbapenenmases. The invention further refers to a method for the phenotypic detection of resistant bacteria, in particular 3MRGN or 4MRGN, by releasing the enzymes of a bacterial culture into a lysate during lysis and then subjecting the lysate, as the sample to be analyzed, to an aforementioned method in order to phenotypically detect the presence of resistance-conferring carbapenemases.

Sensing devices

A sensing device includes a first sensor configured to capture a first analyte in a fluid medium and to generate a first signal in response to capturing the first analyte. The sensing device also includes a second sensor configured to capture a second analyte in the fluid medium and to generate a second signal in response to capturing the second analyte, where the second analyte is different from the first analyte. The sensing device further includes a detector configured to collect the first and second signals to provide a total signal and to calculate a total concentration of the first and the second analyte in the fluid medium based on the total signal.

Engineered hERG channel proteins, vesicles and methods of identifying small molecule pharmacological agents

The present invention provides methods and compositions relating to an assay for hERG channel protein sensitivity to small molecule pharmacological agents. In one embodiment, the invention includes an engineered hERG channel protein. In another embodiment, the invention includes a method of identifying small molecule pharmacological agents that interfere with repolarization of cardiac cells.

Blood unit tests kit
11579153 · 2023-02-14 · ·

A diagnostic biological array, kit or system, and method of using same unit for conducting simultaneously blood tests and determining the presence of diseases, the blood type, and blood quality of a blood sample and its applications.